{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:53:42Z","timestamp":1794959622244,"version":"4.9.1"},"reference-count":198,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eururo.2026.04.009","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:10:04Z","timestamp":1784099404000},"page":"389-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) \u2013 A Summary of the 2026 Guidelines Update"],"prefix":"10.1016","volume":"90","author":[{"given":"Paolo","family":"Gontero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramananthan","family":"Mariappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavan P.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Liedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Yuen-Chun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Baard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Birtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maresa","family":"Botha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otakar","family":"Capoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Fiorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos N.","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Dominguez-Escrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.04.009_b0005","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2026.04.009_b0010","series-title":"Estimated number of new cases in 2022, worldwide, both sexes, all ages","author":"International Agency for Research on Cancer","year":"2022"},{"key":"10.1016\/j.eururo.2026.04.009_b0015","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00428-015-1739-2","article-title":"Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old","volume":"466","author":"Comp\u00e9rat","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.eururo.2026.04.009_b0020","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0025","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11255-016-1491-9","article-title":"WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach","volume":"49","author":"Otto","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2026.04.009_b0030","series-title":"TNM classification of malignant tumours","author":"Brierley","year":"2025"},{"key":"10.1016\/j.eururo.2026.04.009_b0035","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2011.10.026","article-title":"A new and highly prognostic system to discern T1 bladder cancer substage","volume":"61","author":"van Rhijn","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0040","series-title":"WHO classification of tumours: urinary and male genital tumours","author":"WHO Classification of Tumours Editorial Board","year":"2022"},{"key":"10.1016\/j.eururo.2026.04.009_b0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/21681805.2021.1928746","article-title":"The diagnostic challenge of suspicious or positive malignant urine cytology findings when cystoscopy findings are normal: an outpatient blue-light flexible cystoscopy may solve the problem","volume":"55","author":"Andersson","year":"2021","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0050","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1078-1439(99)00020-4","article-title":"Updated concepts and treatment of carcinoma in situ","volume":"4","author":"Lamm","year":"1998","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.euo.2020.12.002","article-title":"Prognostic value of the WHO1973 and WHO2004\/2016 classification systems for grade in primary Ta\/T1 non-muscle-invasive bladder cancer: a multicenter European Association of Urology non-muscle-invasive bladder cancer guidelines panel study","volume":"4","author":"van Rhijn","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0060","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.eururo.2024.08.013","article-title":"The importance of being Grade 3: A plea for a three-tier hybrid classification system for grade in primary non-muscle-invasive bladder cancer","volume":"86","author":"Beijert","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0065","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bju.16828","article-title":"Enhanced prognostic value of four-tier hybrid grading system in Ta Non-muscle-invasive bladder cancer","volume":"136","author":"Ferro","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bju.14417","article-title":"A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens","volume":"123","author":"Mari","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0075","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jmoldx.2022.05.006","article-title":"The Lund molecular taxonomy applied to non-muscle-invasive urothelial carcinoma","volume":"24","author":"Marzouka","year":"2022","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.eururo.2026.04.009_b0080","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bju.13345","article-title":"Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer","volume":"117","author":"Ramirez","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0085","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00261-017-1249-6","article-title":"Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results","volume":"43","author":"Trinh","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.eururo.2026.04.009_b0090","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1007\/s00330-006-0386-z","article-title":"Understanding multislice CT urography techniques: many roads lead to Rome","volume":"16","author":"Nolte-Ernsting","year":"2006","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2026.04.009_b0095","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.juro.2018.04.065","article-title":"Can renal and bladder ultrasound replace computerized tomography urogram in patients investigated for microscopic hematuria?","volume":"200","author":"Tan","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00345-025-05473-z","article-title":"Utility of MRI in NMIBC and feasibility of avoiding Re-TURB in carefully selected patients: a systematic review","volume":"43","author":"Saouli","year":"2025","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0105","doi-asserted-by":"crossref","first-page":"66.e25","DOI":"10.1016\/j.urolonc.2014.06.008","article-title":"Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer","volume":"33","author":"Yafi","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0110","series-title":"The Paris system for reporting urinary cytology","author":"Wojcik","year":"2022"},{"key":"10.1016\/j.eururo.2026.04.009_b0115","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.euo.2021.10.003","article-title":"Diagnostic accuracy of novel urinary biomarker tests in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis","volume":"4","author":"Laukhtina","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/JU.0000000000003991","article-title":"A multicenter prospective randomized controlled trial comparing Cxbladder triage to cystoscopy in patients with microhematuria: the safe testing of risk for asymptomatic microhematuria trial","volume":"212","author":"Lotan","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0125","doi-asserted-by":"crossref","first-page":"163.e1","DOI":"10.1016\/j.urolonc.2021.08.017","article-title":"Xpert bladder cancer monitor in surveillance of bladder cancer: systematic review and meta-analysis","volume":"40","author":"Sharma","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0130","doi-asserted-by":"crossref","first-page":"12489","DOI":"10.3390\/ijms241512489","article-title":"Bladder Epicheck test: A novel tool to support urothelial carcinoma diagnosis in urine samples","volume":"24","author":"Fiorentino","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eururo.2026.04.009_b0135","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.juro.2016.12.010","article-title":"Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study","volume":"197","author":"Kavalieris","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0140","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3390\/cancers16040753","article-title":"Urine-based biomarker test Uromonitor\u00ae in the detection and disease monitoring of non-muscle-invasive bladder cancer-A systematic review and meta-analysis of diagnostic test performance","volume":"16","author":"Kravchuk","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2026.04.009_b0145","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/JU.0000000000004335","article-title":"Uromonitor: clinical validation and performance assessment of a urinary biomarker within the surveillance of patients with nonmuscle-invasive bladder cancer","volume":"213","author":"Ramos","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.euo.2022.03.005","article-title":"Highly sensitive and specific detection of bladder cancer via targeted ultra-deep sequencing of urinary DNA","volume":"6","author":"Ward","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.eururo.2026.04.009_b0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1442-2042.1995.tb00475.x","article-title":"Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra","volume":"2","author":"Kurth","year":"1995","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0160","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.eururo.2024.04.015","article-title":"Transurethral en bloc resection versus standard resection of bladder tumour: a randomised, multicentre, Phase 3 trial","volume":"86","author":"Teoh","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0165","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1097\/JS9.0000000000002291","article-title":"An updated systematic review, meta-analysis, and trial sequential analysis of the efficacy and safety of en bloc transurethral resection vs. conventional transurethral resection for nonmuscle-invasive bladder tumor","volume":"111","author":"Xu","year":"2025","journal-title":"Int J Surg"},{"key":"10.1016\/j.eururo.2026.04.009_b0170","doi-asserted-by":"crossref","first-page":"176.e1","DOI":"10.1016\/j.urolonc.2024.02.006","article-title":"The assessment of bladder cancer resectability with bimanual palpation: a prospective study in laparoscopy and open cystectomy patients","volume":"42","author":"Czech","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0175","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bju.14557","article-title":"Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour","volume":"123","author":"Suarez-Ibarrola","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0180","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000019859","article-title":"Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee","volume":"35","author":"van der Meijden","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0185","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1442-2042.2008.02241.x","article-title":"Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases","volume":"16","author":"Hara","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0190","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0195","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2005.05.021","article-title":"Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder","volume":"48","author":"Mungan","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0200","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1007\/s00345-019-02673-2","article-title":"Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer","volume":"37","author":"Brant","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S0266462310001364","article-title":"Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis","volume":"27","author":"Mowatt","year":"2011","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.eururo.2026.04.009_b0210","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.euros.2021.06.011","article-title":"Time to turn on the blue lights: A systematic review and meta-analysis of photodynamic diagnosis for bladder cancer","volume":"31","author":"Veeratterapillay","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2026.04.009_b0215","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bju.15723","article-title":"Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane Review","volume":"130","author":"Maisch","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2022.103220","article-title":"Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: a systematic review and meta-analysis of randomized controlled trials","volume":"41","author":"Zhao","year":"2023","journal-title":"Photodiagn Photodyn Ther"},{"key":"10.1016\/j.eururo.2026.04.009_b0225","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200092","article-title":"A randomized trial of PHOTOdynamic surgery in non\u2013muscle-invasive bladder cancer","volume":"1","author":"Heer","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.eururo.2026.04.009_b0230","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/21681805.2017.1295101","article-title":"Clinical relevance of narrow-band imaging in flexible cystoscopy: the DaBlaCa-7 study","volume":"51","author":"Drejer","year":"2017","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0235","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.1038\/srep10905","article-title":"A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study","volume":"5","author":"Ye","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2026.04.009_b0240","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4111\/icu.2018.59.2.98","article-title":"Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: prospective, randomized comparison with white light cystoscopy","volume":"59","author":"Kim","year":"2018","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0245","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2016.03.053","volume":"70","author":"Naito","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0250","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.3390\/cancers13174378","article-title":"Performance of narrow band imaging (NBI) and photodynamic diagnosis (PDD) fluorescence imaging compared to white light cystoscopy (WLC) in detecting non-muscle invasive bladder cancer: a systematic review and lesion-level diagnostic meta-analysis","volume":"13","author":"Russo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2026.04.009_b0255","article-title":"Novel visualization methods assisted transurethral resection for bladder cancer: an updated survival-based systematic review and meta-analysis","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0260","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.euf.2023.07.002","article-title":"Repeat transurethral resection for non-muscle-invasive bladder cancer: an updated systematic review and meta-analysis in the contemporary era","volume":"10","author":"Yanagisawa","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.04.009_b0265","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s10147-019-01581-0","article-title":"The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial","volume":"25","author":"Eroglu","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0270","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4111\/icu.20210314","article-title":"Evaluating the efficacy of secondary transurethral resection of the bladder for high-grade Ta tumors","volume":"63","author":"Lee","year":"2022","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0275","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.euf.2017.10.004","article-title":"Long-term outcomes from re-resection for high-risk non-muscle-invasive bladder cancer: A potential to rationalize use","volume":"5","author":"Gordon","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.04.009_b0280","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/0974-7796.163798","article-title":"Results of second transurethral resection for high-grade T1 bladder cancer","volume":"8","author":"Hashine","year":"2016","journal-title":"Urol Ann"},{"key":"10.1016\/j.eururo.2026.04.009_b0285","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00345-018-2299-2","article-title":"Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought","volume":"36","author":"Palou","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0290","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/bju.13102","article-title":"Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical bacillus Calmette-Guerin","volume":"116","author":"Baltac\u0131","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0295","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/PAP.0000000000000152","article-title":"Challenges in pathologic staging of bladder cancer: proposals for fresh approaches of assessing pathologic stage in light of recent studies and observations pertaining to bladder histoanatomic variances","volume":"24","author":"Paner","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.eururo.2026.04.009_b0300","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0305","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0310","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage ta-T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0315","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0320","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin N Am"},{"key":"10.1016\/j.eururo.2026.04.009_b0325","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0022-5347(05)67974-8","article-title":"Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results","volume":"163","author":"Losa","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0330","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/S0022-5347(05)64994-4","article-title":"Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance","volume":"167","author":"Griffiths","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0335","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1442-2042.2008.02012.x","article-title":"Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder","volume":"15","author":"Takenaka","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0340","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","article-title":"The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables","volume":"60","author":"Fernandez-Gomez","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0345","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.urology.2008.12.047","article-title":"Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors","volume":"73","author":"Palou","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.04.009_b0350","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clgc.2020.07.011","article-title":"Bladder cancer: A comparison between non-urothelial variant histology and urothelial carcinoma across all stages and treatment modalities","volume":"19","author":"Deuker","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.04.009_b0355","doi-asserted-by":"crossref","unstructured":"Kwong JCC, Al-Daqqaq Z, Chelliahpillai Y, et al. Development and international evaluation of an artificial intelligence-based model (PROGRxN-BCa) using the World Health Organization 2004\/2022 grading system to predict progression risk and improve substratification for non-muscle-invasive bladder cancer. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4145.","DOI":"10.1016\/j.eururo.2025.09.4145"},{"key":"10.1016\/j.eururo.2026.04.009_b0360","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the international bladder cancer group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0365","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.euo.2024.06.004","article-title":"Clinical validation of the intermediate-risk non-muscle-invasive bladder cancer scoring system and substratification model proposed by the international bladder cancer group: a multicenter Young academic urologists urothelial working group collaboration","volume":"7","author":"Soria","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0370","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0375","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0380","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.eururo.2026.04.009_b0385","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO-25-01651","article-title":"TAR-200 for bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the Phase IIb SunRISe-1 study","volume":"43","author":"Daneshmand","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0390","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0395","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2026.04.009_b0400","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0405","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0410","doi-asserted-by":"crossref","first-page":"520.e1","DOI":"10.1016\/j.urolonc.2025.03.024","article-title":"Intravesical gemcitabine and docetaxel in patients with recurrent high-grade nonmuscle invasive bladder cancer-a prospective cohort study","volume":"43","author":"Pijpers","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0415","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0420","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0425","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-024-03025-3","article-title":"Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial","volume":"30","author":"Li","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2026.04.009_b0430","unstructured":"European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics; 2019. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/quinolone-fluoroquinolone-containing-medicinal-products."},{"key":"10.1016\/j.eururo.2026.04.009_b0435","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1007\/s00432-022-04464-6","article-title":"The impact of smoking on recurrence and progression of non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"149","author":"\u015alusarczyk","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0440","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3233\/BLC-211583","article-title":"Association between smoking and overall and specific mortality in patients with bladder cancer: a population-based study","volume":"8","author":"Ho","year":"2022","journal-title":"Bladder Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.eururo.2026.04.009_b0445","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers17040713","article-title":"Perioperative intensive Smoking Cessation intervention among smokers who underwent transurethral resection of bladder tumor (TURBT) in two different settings: a randomized controlled trial","volume":"17","author":"Lydom","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2026.04.009_b0450","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2022.08.012","volume":"83","author":"Pedersen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0455","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.juro.2006.10.048","article-title":"Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades","volume":"177","author":"Mariappan","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0460","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/01.ju.0000149163.08521.69","article-title":"A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database","volume":"173","author":"Mariappan","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0465","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bju.13536","article-title":"Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder cancer Italian Active Surveillance (BIAS) project","volume":"118","author":"Hurle","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0470","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/JU.0000000000003639","article-title":"International bladder cancer group intermediate-risk nonmuscle-invasive bladder cancer scoring system predicts outcomes of patients on active surveillance","volume":"210","author":"Tan","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0475","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00345-019-02628-7","article-title":"Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors","volume":"37","author":"Zhou","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0480","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.21873\/anticanres.17636","article-title":"Randomized study of short-time continuous saline irrigation after transurethral resection in non-muscle invasive bladder cancer","volume":"45","author":"Onishi","year":"2025","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2026.04.009_b0485","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0490","doi-asserted-by":"crossref","first-page":"477","DOI":"10.6004\/jnccn.2013.0060","article-title":"Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"11","author":"Abern","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2026.04.009_b0495","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eururo.2013.06.009","article-title":"Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review","volume":"64","author":"Perlis","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0500","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/bju.15336","article-title":"What influences adherence to guidance for postoperative instillation of intravesical chemotherapy to patients with bladder cancer?","volume":"128","author":"Dunsmore","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0505","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0510","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2026.04.009_b0515","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.eururo.2017.06.038","article-title":"Value of an Immediate intravesical Instillation of mitomycin C in Patients with non-muscle-invasive Bladder Cancer: a prospective multicentre randomised study in 2243 patients","volume":"73","author":"Bosschieter","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0520","doi-asserted-by":"crossref","first-page":"400.e7","DOI":"10.1016\/j.urolonc.2018.05.026","article-title":"An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups","volume":"36","author":"Bosschieter","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0525","doi-asserted-by":"crossref","first-page":"179.e9","DOI":"10.1016\/j.urolonc.2018.10.019","article-title":"The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: a preliminary results of randomized controlled trial","volume":"37","author":"Elsawy","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0530","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.euf.2018.08.019","article-title":"Systematic review on the utilization of maintenance intravesical chemotherapy in the management of non-muscle-invasive bladder cancer","volume":"4","author":"Tabayoyong","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.04.009_b0535","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","article-title":"The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials","volume":"53","author":"Sylvester","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0540","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2026.04.009_b0545","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bju.15571","article-title":"Intravesical mitomycin C (MMC) and MMC\u2009+\u2009cytosine arabinoside for non-muscle-invasive bladder cancer: a randomised clinical trial","volume":"129","author":"Miyata","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0550","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1464-410X.1989.tb05159.x","article-title":"Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times","volume":"63","author":"Giesbers","year":"1989","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0555","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.eururo.2003.12.010","volume":"45","author":"Kuroda","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0560","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0565","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2022.08.003","article-title":"Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): A Phase 2, open-label, randomised controlled trial","volume":"83","author":"Tan","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0570","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euo.2022.10.008","article-title":"Hyperthermic mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: results of the HIVEC-1 trial","volume":"6","author":"Angulo","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0575","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0580","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0585","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0590","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0595","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.04.009_b0600","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0605","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0610","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0615","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"J\u00e4rvinen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0620","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0625","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2026.04.009_b0630","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0635","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/01.coc.0000135570.37287.7f","article-title":"The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy","volume":"27","author":"Huncharek","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0640","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","article-title":"Efficacy of bacillus Calmette-Guerin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0645","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.urolonc.2016.11.016","article-title":"Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer","volume":"35","author":"Steinberg","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0650","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0655","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.euf.2022.06.002","article-title":"Effect of levofloxacin on the efficacy and adverse events in intravesical bacillus Calmette-Guerin treatment for bladder cancer: results of a randomized, prospective, multicenter study","volume":"8","author":"Numakura","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.04.009_b0660","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0665","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical Bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.04.009_b0670","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0675","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0680","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0685","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0690","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4111\/icu.20210340","article-title":"Low-dose versus standard-dose Bacille Calmette-Guerin for non-muscle-invasive bladder cancer: systematic review and meta-analysis of randomized controlled trials","volume":"63","author":"Choi","year":"2022","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0695","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","volume":"67","author":"Solsona","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0700","doi-asserted-by":"crossref","first-page":"e2572","DOI":"10.1097\/MD.0000000000002572","article-title":"Combination of intravesical chemotherapy and bacillus Calmette-Guerin versus bacillus Calmette-Guerin monotherapy in intermediate- and high-risk nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"95","author":"Cui","year":"2016","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.eururo.2026.04.009_b0705","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fonc.2019.00121","article-title":"Combination of intravesical Bacille Calmette-Guerin and Chemotherapy vs. Bacille Calmette-Guerin Alone in non-muscle invasive bladder cancer: a meta-analysis","volume":"9","author":"Huang","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0710","article-title":"Intravesical bacillus Calmette-Guerin with interferon-alpha versus intravesical bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer","volume":"3","author":"Shepherd","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2026.04.009_b0715","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2015.02.022","volume":"68","author":"J\u00e4rvinen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0720","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0725","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.euo.2024.12.005","article-title":"Oncologic outcomes of sequential intravesical gemcitabine and docetaxel compared with bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer","volume":"8","author":"Taylor","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0730","doi-asserted-by":"crossref","first-page":"9.e1","DOI":"10.1016\/j.urolonc.2021.03.024","article-title":"Intravesical sequential gemcitabine and docetaxel versus bacillus Calmette-Guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG","volume":"40","author":"Steinberg","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0735","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/JU.0000000000002740","article-title":"Sequential intravesical gemcitabine and docetaxel for bacillus Calmette-Guerin-Naive high-risk nonmuscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0740","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.euf.2024.09.006","article-title":"Comparative effectiveness of bacillus Calmette-Guerin and sequential intravesical gemcitabine and docetaxel for treatment-naive intermediate-risk non-muscle-invasive bladder cancer","volume":"11","author":"Kolanukuduru","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.04.009_b0745","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2026.04.009_b0750","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.04.009_b0755","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","article-title":"ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)","volume":"37","author":"Roupret","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0760","first-page":"883","article-title":"The benefit of a neoadjuvant instillation of chemotherapy in non-muscle invasive bladder cancer: interim analysis of the PRECAVE randomized clinical trial","volume":"74","author":"Carri\u00f3n","year":"2021","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0765","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/JU.0000000000003002","article-title":"Clinical efficacy of neoadjuvant intravesical mitomycin-C therapy immediately before transurethral resection of bladder tumor in patients with nonmuscle-invasive bladder cancer: preliminary results of a prospective, randomized Phase II study","volume":"209","author":"Lee","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0770","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bju.15038","article-title":"Caliber: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer","volume":"125","author":"Mostafid","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0775","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.22.00470","article-title":"DaBlaCa-13 study: oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer: primary outcome of a randomized controlled trial","volume":"41","author":"Lindgren","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0780","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/JU.0000000000003645","article-title":"Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 \u00b1 transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, Phase 3 trial (ATLAS)","volume":"210","author":"Prasad","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0785","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JU.0000000000004296","article-title":"Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: a single-arm, open-label, Phase 3 trial (ENVISION)-Label","volume":"213","author":"Prasad","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0790","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bju.13146","article-title":"Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy","volume":"117","author":"Moschini","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0795","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0800","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.juro.2014.09.092","article-title":"Clinical outcomes of cT1 micropapillary bladder cancer","volume":"193","author":"Willis","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0805","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0022-5347(05)00423-4","article-title":"The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma","volume":"175","author":"Kamat","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0810","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bju.16675","article-title":"Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer","volume":"136","author":"Scilipoti","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0815","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/bju.16686","article-title":"Long-term multicentre analysis of robot-assisted radical cystectomy for non-muscle-invasive bladder cancer","volume":"136","author":"Tillu","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0820","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0825","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.urolonc.2007.12.011","article-title":"The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Guerin immunotherapy","volume":"27","author":"Gofrit","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0830","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0835","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000049765","article-title":"Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC Gu Group phase II protocol 30861","volume":"40","author":"Jakse","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0840","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0845","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/21681805.2016.1210672","article-title":"Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder","volume":"50","author":"Kaasinen","year":"2016","journal-title":"Scand J Urol"},{"issue":"Suppl.","key":"10.1016\/j.eururo.2026.04.009_b0850","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2006.05.059","article-title":"Urothelial carcinoma of the prostate","volume":"69","author":"Palou","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.04.009_b0855","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","article-title":"Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer","volume":"27","author":"Lerner","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0860","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0865","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Guerin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"issue":"Suppl. 1","key":"10.1016\/j.eururo.2026.04.009_b0870","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","article-title":"High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder","volume":"66","author":"Sylvester","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.04.009_b0875","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0880","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0885","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International bladder cancer group consensus statement on clinical trial design for patients with bacillus Calmette-Guerin-exposed high-risk non-muscle-invasive bladder cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0890","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous Bacille Calmette-Guerin failure pattern on subsequent response to Bacille Calmette-Guerin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.04.009_b0895","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events","volume":"7","author":"Witjes","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2026.04.009_b0900","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bju.13088","article-title":"Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer","volume":"117","author":"Cockerill","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0905","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"1","author":"Jones","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2026.04.009_b0910","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","article-title":"Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guerin","volume":"193","author":"Morales","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0915","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2b for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0920","first-page":"44","article-title":"FDA approves pembrolizumab for BCG-unresponsive NMIBC","volume":"34","author":"Wright","year":"2020","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.eururo.2026.04.009_b0925","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFN\u03b1\/Syn3 for patients with high-grade, bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a Phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0930","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0935","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","article-title":"Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer","volume":"35","author":"Catto","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0940","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.juro.2011.04.073","article-title":"Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma in situ","volume":"186","author":"Rosevear","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0945","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.urolonc.2009.04.008","article-title":"A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions?","volume":"29","author":"Kurpad","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0950","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.urolonc.2009.03.025","article-title":"Second opinion pathology in tertiary care of patients with urologic malignancies","volume":"29","author":"Wayment","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0955","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5489\/cuaj.4126","article-title":"Pathology review impacts clinical management of patients with T1-T2 bladder cancer","volume":"11","author":"Traboulsi","year":"2017","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2026.04.009_b0960","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.urology.2016.01.048","article-title":"Change in management based on pathologic second opinion among bladder cancer patients presenting to a Comprehensive Cancer Center: implications for clinical practice","volume":"93","author":"Luchey","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.04.009_b0965","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2012.05.008","article-title":"Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature","volume":"62","author":"Soukup","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0970","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.euo.2025.04.020","article-title":"Results of the prospective randomized UroFollow trial comparing marker-guided versus cystoscopy-based surveillance in patients with low\/intermediate-risk bladder cancer","volume":"8","author":"Schmitz-Dr\u00e4ger","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.009_b0975","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2025.03.018","article-title":"Use of the Xpert bladder cancer monitor urinary biomarker test for guiding cystoscopy in high-grade non-muscle-invasive bladder cancer: results from the randomized controlled DaBlaCa-15 trial","volume":"88","author":"Dreyer","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0980","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bju.14368","article-title":"Evaluating patient-reported outcome measures (PROMs) for bladder cancer: a systematic review using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist","volume":"122","author":"Mason","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.009_b0985","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2020.03.043","article-title":"Propensity for quality: no longer a tenuous proposition in bladder cancer","volume":"78","author":"Mariappan","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.009_b0990","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.euo.2024.08.001","article-title":"Deintensification of treatment for low-grade bladder tumors: A collaborative review by the international bladder cancer group (IBCG)","volume":"8","author":"Contieri","year":"2025","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826021111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826021111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:33:59Z","timestamp":1791837239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826021111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":198,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0302283826021111"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.04.009","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) \u2013 A Summary of the 2026 Guidelines Update","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}